Skip to main navigation

preloader

Overview
News & Events
- News Releases
- Events
Presentations
SEC Filings
Stock Info
- Analyst Coverage
Corporate Governance
Resources & Contact

News Releases

Year

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 16, 2022

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

May 12, 2022

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2022

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

April 27, 2022

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

April 5, 2022

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

March 28, 2022

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 17, 2022

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

March 17, 2022

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

March 9, 2022

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Displaying 21 - 30 of 36

Investor Tools

News & Events
- News Releases
- Events

Stock Info
- Stock Quote & Chart

Corporate Governance

Financials & Filings

IR Resources

Copyright © 2022 Cullinan Oncology, Inc.. All rights reserved

Site - Footer

Terms of Use/Privacy